Evidence map›Paper›PMID 28386331›Full record

ArticleAmerican journal of translational research2017

PKC/NADPH oxidase are involved in the protective effect of pioglitazone in high homocysteine-induced paracrine dyfunction in endothelial progenitor cells.

Shengjie Xu, Yanbo Zhao, Chongying Jin, Lu Yu, Fang Ding, Guosheng Fu, Junhui Zhu

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shengjie XuDepartment of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University Hangzhou 310016, China.
Yanbo ZhaoDepartment of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University Hangzhou 310016, China.
Chongying JinDepartment of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University Hangzhou 310016, China.
Lu YuDepartment of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University Hangzhou 310016, China.
Fang DingThe Province Center for Cardio-Cerebral-Vascular Disease, Zhejiang Hospital Hangzhou, Zhejiang, China.
Guosheng FuDepartment of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University Hangzhou 310016, China.
Junhui ZhuDepartment of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University Hangzhou 310016, China.
Sir Run Run Shaw Hospital · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence suggests that EPCs improve neovascularization and endothelial regeneration via the production of paracrine factors. VEGF and IL-8 are major cytokines involved in EPC-mediated angiogenesis and re-endothelialization. In our previous studies, Hcy impaired EPC migratory and adhesive activities. We devised this study to determine whether Hcy could affect the expression and secretion of VEGF and IL-8 from EPCs. We found that high levels of Hcy (100-500 μM) decreased the EPC-mediated protein secretion and mRNA expression of VEGF and IL-8. Moreover, PIO, a PPARγ agonist, has been suggested to regulate EPC adhesion, migration, survival. In this study, PIO normalized the production of these cytokines by EPCs stimulated with Hcy. These effects of Hcy and PIO were primarily mediated by PKC and ROS via NADPH oxidase. We further confirmed this mechanism via knockdown of the NADPH oxidase subunits p67phox and Nox2. Furthermore, the PPARγ inhibitor GW9662 was not observed to abrogate the beneficial effect of PIO, indicating that PIO protected EPC paracrine function against Hcy in a PPARγ-independent manner.

Indexed as

p67phoxParacrine cytokinesreactive oxygen speciessiRNA

Identifiers

PMID28386331
PMCPMC5375996
OpenAlexW3022803516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.